Shares of Aduro BioTech Inc (NASDAQ:ADRO) have received an average recommendation of “Hold” from the eleven research firms that are covering the stock, MarketBeat reports. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $12.80.
A number of brokerages recently issued reports on ADRO. BidaskClub downgraded shares of Aduro BioTech from a “hold” rating to a “sell” rating in a report on Saturday. ValuEngine downgraded shares of Aduro BioTech from a “sell” rating to a “strong sell” rating in a report on Friday, April 6th. Canaccord Genuity reissued a “buy” rating on shares of Aduro BioTech in a report on Friday, March 2nd. Bank of America lowered their price target on shares of Aduro BioTech from $9.00 to $8.00 and set an “underperform” rating on the stock in a report on Friday, March 2nd. Finally, HC Wainwright set a $10.00 price target on shares of Aduro BioTech and gave the stock a “buy” rating in a report on Friday, March 2nd.
NASDAQ ADRO traded down $0.15 during mid-day trading on Wednesday, reaching $6.95. 380,297 shares of the stock were exchanged, compared to its average volume of 520,108. Aduro BioTech has a 1 year low of $5.82 and a 1 year high of $14.05.
Aduro BioTech (NASDAQ:ADRO) last announced its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.01. Aduro BioTech had a negative net margin of 532.88% and a negative return on equity of 37.86%. The firm had revenue of $3.76 million for the quarter, compared to the consensus estimate of $4.32 million. research analysts anticipate that Aduro BioTech will post -1.28 EPS for the current year.
In other Aduro BioTech news, insider Stephen T. Isaacs sold 40,000 shares of the company’s stock in a transaction on Monday, April 2nd. The shares were sold at an average price of $8.91, for a total transaction of $356,400.00. Following the completion of the transaction, the insider now directly owns 245,746 shares in the company, valued at $2,189,596.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Stephen T. Isaacs sold 72,051 shares of the company’s stock in a transaction on Friday, March 9th. The stock was sold at an average price of $8.48, for a total transaction of $610,992.48. Following the transaction, the insider now owns 231,380 shares of the company’s stock, valued at $1,962,102.40. The disclosure for this sale can be found here. Insiders have sold 118,925 shares of company stock valued at $1,011,936 over the last 90 days. 6.60% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the business. MetLife Investment Advisors LLC acquired a new stake in shares of Aduro BioTech in the fourth quarter valued at about $140,000. SG Americas Securities LLC acquired a new stake in shares of Aduro BioTech in the third quarter valued at about $167,000. Fox Run Management L.L.C. raised its position in shares of Aduro BioTech by 91.4% in the fourth quarter. Fox Run Management L.L.C. now owns 22,775 shares of the biotechnology company’s stock valued at $171,000 after buying an additional 10,875 shares during the last quarter. Nisa Investment Advisors LLC raised its position in shares of Aduro BioTech by 2,294.1% in the fourth quarter. Nisa Investment Advisors LLC now owns 24,420 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 23,400 shares during the last quarter. Finally, Wilbanks Smith & Thomas Asset Management LLC acquired a new stake in shares of Aduro BioTech in the fourth quarter valued at about $191,000. Institutional investors own 44.91% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/21/aduro-biotech-inc-adro-receives-12-80-consensus-pt-from-analysts.html.
Aduro BioTech Company Profile
Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.